4/18
09:00 am
cogt
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
Low
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
4/9
09:04 am
cogt
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor [Yahoo! Finance]
Medium
Report
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor [Yahoo! Finance]
4/9
09:00 am
cogt
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Medium
Report
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
2/28
05:30 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
2/28
04:49 am
cogt
COGT Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
COGT Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
2/27
01:08 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.
2/26
12:16 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $11.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $11.00 to $13.00. They now have a "buy" rating on the stock.
2/26
08:18 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/26
08:10 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
2/26
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2/26
07:31 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $14.00.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $14.00.
2/23
08:23 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Wedbush from $5.00 to $10.00. They now have a "neutral" rating on the stock.
High
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Wedbush from $5.00 to $10.00. They now have a "neutral" rating on the stock.
2/22
02:37 pm
cogt
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis [Yahoo! Finance]
Medium
Report
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis [Yahoo! Finance]
2/22
02:30 pm
cogt
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Low
Report
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
2/15
03:34 am
cogt
Steven Cohen's Point72 Asset Management Bolsters Position in Cogent Biosciences [Yahoo! Finance]
Medium
Report
Steven Cohen's Point72 Asset Management Bolsters Position in Cogent Biosciences [Yahoo! Finance]
2/14
03:41 pm
cogt
Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst [Seeking Alpha]
Neutral
Report
Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst [Seeking Alpha]
2/14
01:57 pm
cogt
DTSS, TNON and BREA among mid-day movers [Seeking Alpha]
Low
Report
DTSS, TNON and BREA among mid-day movers [Seeking Alpha]
2/14
07:12 am
cogt
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement [Yahoo! Finance]
High
Report
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement [Yahoo! Finance]
2/14
07:00 am
cogt
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
High
Report
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
2/12
08:09 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
2/8
07:16 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $11.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $11.00 price target on the stock.
2/5
09:00 am
cogt
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
High
Report
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting